Local recurrence in melanoma in situ: influence of sex, age, site of involvement and therapeutic modalities

Zalaudek, Iris; Horn, Michael; Richtig, Erika; Hödl, S; Kerl, Helmut; Smolle, Josef

doi:10.1046/j.1365-2133.2003.05155.x

Cited by 93 publications

(72 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…45 Although a visible inflammatory response usually is associated with treatment success, the inflammatory response and apparent macroscopic clearance were not reliable means of assessing therapeutic success. Imiquimod could be used as an adjunct field treatment before or after surgical excision to decrease recurrence rates and also may have a role in the management of LM when surgery is contraindicated.…”

Section: Commentmentioning

confidence: 99%

Efficacy of Imiquimod Cream, 5%, for Lentigo Maligna After Complete Excision

Ly¹

2011

Arch Dermatol

View full text Add to dashboard Cite

Setting: A multidisciplinary melanoma clinic at a major tertiary hospital.Patients: Forty-three patients with biopsy-proven LM of greater than 5 mm in diameter completed this study.Interventions: Imiquimod cream, 5%, was applied to the lesion 5 days a week for 12 weeks. The original lesion was excised with a 5-mm margin. Main Outcome Measures:The primary outcome was histopathologic evidence of LM in the excision specimen assessed independently by 2 of 3 dermatopathologists. Visible inflammation during treatment and macroscopic clearance were recorded.

show abstract

Section: Commentmentioning

confidence: 99%

Efficacy of Imiquimod Cream, 5%, for Lentigo Maligna After Complete Excision

Ly¹

2011

Arch Dermatol

View full text Add to dashboard Cite

show abstract

“…In contrast, despite the above considerations, CMIS is linked to some health concerns and unsolved debates regarding its clinicopathologic diagnosis [19 -24], therapeutic/follow-up management [20,[25][26][27][28][29], and prognostic relevance [24, 30 -32].…”

Section: Introductionmentioning

confidence: 99%

Cutaneous Melanoma In Situ: Translational Evidence from a Large Population-Based Study

Mocellin

Nitti

2011

The Oncologist

View full text Add to dashboard Cite

Background. Cutaneous melanoma in situ (CMIS) is a nosologic entity surrounded by health concerns and unsolved debates. We aimed to shed some light on CMIS by means of a large population-based study. Methods. Patients with histologic diagnosis of CMIS were identified from the Surveillance Epidemiology End Results (SEER) database.Results. The records of 93,863 cases of CMIS were available for analysis. CMIS incidence has been steadily increasing over the past 3 decades at a rate higher than any other in situ or invasive tumor, including invasive skin melanoma (annual percentage change [APC]: 9.5% versus 3.6%, respectively). Despite its noninvasive nature, CMIS is treated with excision margins wider than 1 cm in more than one third of cases. CMIS is associated with an increased risk of invasive melanoma (standardized incidence ratio [SIR]: 8.08; 95% confi-

show abstract

“…The success rates have been poor with a 34% incidence of recurrence [63]. No prospective studies on the use of laser in LM have been published and reports have been limited to single cases and small groups.…”

Section: Laser Therapymentioning

confidence: 92%

“…The method of twice repeated freeze time of 45-60 sec with an apparent 1.0 cm margin of lateral tissue destruction has been reported to have a recurrence rate of 6.6% at 3 years. However, articles demonstrate a 34% recurrence rate with liquid nitrogen [63]. The major drawbacks of cryotherapy are ulceration, delay in healing, scar contraction, hypertrophic scar, depigmentation, lack of margin control, and incomplete treatment of disease with epidermal appendages.…”

Section: Cryotherapymentioning

confidence: 96%

Management of lentigo maligna and lentigo maligna melanoma: Seminars in surgical oncology

Arlette

Trotter

et al. 2004

Journal of Surgical Oncology

View full text Add to dashboard Cite

Lentigo maligna (LM) and lentigo maligna melanoma (LMM) represent a character, histogenetic subclass of melanocytic malignancies. They often present with a prolonged phase of slow growth but once invasion has occurred, the prognostic features are identical to all other melanomas. These lesions occur primarily on the head and neck where they evolve from areas of pigmented staining to the more typical features identifiable with malignant melanomas on other skin surfaces. The treatment options and recent advances in management are reviewed.

show abstract

Local recurrence in melanoma in situ: influence of sex, age, site of involvement and therapeutic modalities

Abstract: In MIS, treatment modalities other than surgical excision may be used in certain situations, but carry a significantly increased risk of local recurrence.

Cited by 93 publications

References 34 publications

Efficacy of Imiquimod Cream, 5%, for Lentigo Maligna After Complete Excision

Efficacy of Imiquimod Cream, 5%, for Lentigo Maligna After Complete Excision

Cutaneous Melanoma In Situ: Translational Evidence from a Large Population-Based Study

Management of lentigo maligna and lentigo maligna melanoma: Seminars in surgical oncology

Contact Info

Product

Resources

About